1. FRI0016 R835, A NOVEL IRAK1/4 DUAL INHIBITOR IN CLINICAL DEVELOPMENT, BLOCKS TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING IN HUMAN AND MOUSE. (2nd June 2020) Authors: Lamagna, C.; Gundel, C.; Chan, M.; Young, C.; Braselmann, S.; Frances, R.; Yi, S.; Chen, Y.; Park, G.; Chou, L.; Masuda, E.; Taylor, V. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 579 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0046 TARGETING IRAK1 AND 4 SIGNALING WITH R835, A NOVEL ORAL SMALL MOLECULE INHIBITOR: A POTENTIAL NEW TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS. (2nd June 2020) Authors: Lamagna, C.; Chan, M.; Bagos, A.; Tai, E.; Young, C.; Chen, Y.; Chou, L.; Park, G.; Masuda, E.; Taylor, V. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0133 PRECLINICAL EFFICACY OF R835, A NOVEL IRAK1/4 DUAL INHIBITOR, IN RODENT MODELS OF JOINT INFLAMMATION. (2nd June 2020) Authors: Lamagna, C.; Chan, M.; Tai, E.; Siu, S.; Frances, R.; Yi, S.; Young, C.; Markovtsov, V.; Chen, Y.; Chou, L.; Park, G.; Masuda, E.; Taylor, V. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗